Who Exports Erlotinib from India — 94 Suppliers Behind a $2.7M Market
India's erlotinib export market is supplied by 94 active exporters who collectively shipped $2.7M across 336 shipments. NATCO PHARMA LIMITED leads with a 20.4% market share, followed by MSN LABORATORIES PRIVATE LIMITED and CIPLA LIMITED. The top 5 suppliers together control 69.7% of total export value, reflecting a concentrated market structure.
Top Erlotinib Exporters from India — Ranked by Export Value
NATCO PHARMA LIMITED is the leading erlotinib exporter from India, holding a 20.4% share of the $2.7M market across 336 shipments from 94 exporters. The top 5 suppliers — NATCO PHARMA LIMITED, MSN LABORATORIES PRIVATE LIMITED, CIPLA LIMITED, VEXXA LIFESCIENCES PVT. LTD., ALEMBIC PHARMACEUTICALS LIMITED — collectively control 69.7% of total export value, indicating a moderately concentrated market. Individual shares are: NATCO PHARMA LIMITED (20.4%), MSN LABORATORIES PRIVATE LIMITED (19.8%), CIPLA LIMITED (15.3%), VEXXA LIFESCIENCES PVT. LTD. (9.5%), ALEMBIC PHARMACEUTICALS LIMITED (4.8%).
Top Erlotinib Exporters from India
Ranked by export value · 94 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | NATCO PHARMA LIMITED ERLONAT/ERLOTINIB 150MG TABLETS 30'S (APERLONAT/ERLOTINIB 150MG TABLETS (7680X30ERLONAT/ERLOTINIB 150MG TABLETS 30'SCI NO:123263)NOS | $547.2K | 3 | 20.4% |
| 2 | MSN LABORATORIES PRIVATE LIMITED ERLOTINIB TABLETS 25MG, 30S, AP US DETAILS AS PER INVOICELOTYRO 150MG -ERLOTINIB 150 MG MSN-PENOSERLOTINIB TAB 150MG 30'S NOVADOZ | $529.7K | 6 | 19.8% |
| 3 | CIPLA LIMITED ERLOCIP 150 TABLET (25ERLOCIP 100 TABLET (10 | $409.5K | 2 | 15.3% |
| 4 | VEXXA LIFESCIENCES PVT. LTD. ERVEX 150 BERVEX 150 TABERVEX 150 | $253.4K | 1 | 9.5% |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED ERLOTINIB TABLETS 25MG, 30S, AP US DETAILS AS PER INVOICEERLOTINIB TAB 150MG 30'S NOVADOZERLOTINIB TAB 25 MG - 1 X 30. | $129.5K | 1 | 4.8% |
| 6 | RELIANCE LIFE SCIENCES PRIVATE LIMITED ERLOTINIB 150 MG TABS 1 PACK=3 STPERLOTIREL-150 MG ERLOTINIB 150 MG TABSNOSERLOTIREL-100 MG ERLOTINIB 100 MG TABSNOS | $102.9K | 3 | 3.8% |
| 7 | UNITED BIOTECH PRIVATE LIMITED ERLOTEC 150ERLOCEVA 100 ERLOTINIB 100 MG TABERLOTINIB TABLETS 100MG | $98.8K | 4 | 3.7% |
| 8 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ERLONAT/ERLOTINIB 150MG TABLETS 30'S (APERLONAT/ERLOTINIB 150MG TABLETS (7680X30ERLONAT/ERLOTINIB 150MG TABLETS 30'SCI NO:123263)NOS | $54.2K | 3 | 2.0% |
| 9 | VEXXA LIFESCIENCES PRIVATE LIMITED ERVEX 150 BERVEX 150 TABERVEX 150 | $37.4K | 1 | 1.4% |
| 10 | JODAS EXPOIM PRIVATE LIMITED | $31.3K | 1 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Erlotinib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Warning Letter, November | Yes, February 2024 | No | Not verified | FDA issued a warning letter in November 2023 for CGMP violations at Indore facil |
| ALEMBIC PHARMACEUTICALS LIMITED | Not Listed | Yes, July 2025 | No | Not verified | WHO-GMP compliance confirmed in July 2025 for API Unit I. |
| RELIANCE LIFE SCIENCES PRIVATE LIMITED | Not Listed | Unknown | No | Not verified | Received clarification letter from CDSCO on June 8, 2022. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Not Listed | Unknown | No | Not verified | No specific regulatory actions found in available sources. |
| JODAS EXPOIM PRIVATE LIMITED | Not Listed | Unknown | No | Not verified | No specific regulatory actions found in available sources. |
TransData Nexus reviewed the regulatory standing of 5 leading Erlotinib exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 0 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Erlotinib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% to the nation's bulk drug production. This prominence is bolstered by the presence of major pharmaceutical companies such as NATCO Pharma Limited and MSN Laboratories Private Limited, both leading exporters of Erlotinib. The city's robust infrastructure, including the Hyderabad Pharma City project, further cements its status as a pharmaceutical hub.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and biogenerics manufacturing. (mediaindia.eu) Vadodara, in particular, hosts Alembic Pharmaceuticals Limited, a key exporter of Erlotinib. The region's focus on formulations is supported by a well-established industrial ecosystem and a skilled workforce, making it a strategic location for pharmaceutical production.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Companies like Sun Pharmaceutical Industries Limited, headquartered in Mumbai, leverage the region's extensive port facilities and logistical advantages to distribute products like Erlotinib to international markets. The area's proximity to major shipping routes enhances its role in global pharmaceutical trade.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions, contributing to India's overall pharmaceutical output.
5Sourcing Recommendations
- Engage with Hyderabad-based API Manufacturers: Given Hyderabad's dominance in bulk drug production, sourcing Erlotinib APIs from manufacturers like NATCO Pharma Limited and MSN Laboratories Private Limited can ensure quality and reliability.
- Collaborate with Formulation Specialists in Gujarat: Partnering with companies in the Ahmedabad-Vadodara corridor, such as Alembic Pharmaceuticals Limited, can facilitate access to high-quality Erlotinib formulations.
- Utilize Mumbai's Export Infrastructure: Leveraging the logistical advantages of the Mumbai-Thane-Raigad region can streamline the export process for Erlotinib, ensuring timely delivery to international markets.
- Consider Cost Benefits in Baddi-Nalagarh: Exploring manufacturing opportunities in the Baddi-Nalagarh tax incentive zone may offer cost advantages for producing Erlotinib, enhancing overall profitability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Erlotinib exporters from India
Natco Pharma Limited — Natco Pharma acquires 35.75% stake in Adcock Ingram
In November 2025, Natco Pharma Limited completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. This acquisition led to the delisting of Adcock Ingram from the Johannesburg Stock Exchange. - IMPACT: This strategic move is expected to enhance Natco Pharma's global footprint, potentially increasing its Erlotinib export capabilities.
Impact: This strategic move is expected to enhance Natco Pharma's global footprint, potentially increasing its Erlotinib export capabilities.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
In March 2025, Sun Pharma announced the acquisition of Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: This acquisition may bolster Sun Pharma's oncology portfolio, potentially affecting its position in the Erlotinib market.
Impact: This acquisition may bolster Sun Pharma's oncology portfolio, potentially affecting its position in the Erlotinib market.
Sun Pharmaceutical Industries Limited — Sun Pharma merges with Taro Pharmaceuticals for $347.73 million
In January 2024, Sun Pharma entered into a definitive merger agreement with Taro Pharmaceuticals to acquire the remaining stake in Taro for $347.73 million. - IMPACT: This merger is likely to strengthen Sun Pharma's generic drug portfolio, potentially influencing its Erlotinib exports.
Impact: This merger is likely to strengthen Sun Pharma's generic drug portfolio, potentially influencing its Erlotinib exports.
Common Questions — Erlotinib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which erlotinib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, NATCO PHARMA LIMITED leads with 11 recorded shipments worth $547.2K. MSN LABORATORIES PRIVATE LIMITED (32 shipments) and CIPLA LIMITED (4 shipments) are also established high-volume exporters.
Q How many erlotinib manufacturers are there in India?
India has 94 active erlotinib exporters with a combined export market of $2.7M across 336 shipments to 55 countries. The top 5 suppliers hold 69.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for erlotinib from India?
Average FOB unit price: $47.90 per unit, ranging from $0.04 to $3896.10. Average shipment value: $8.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 94 verified Indian exporters of Erlotinib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 336 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 55 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
336 Verified Shipments
94 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists